Horizon and AstraZeneca Announce Oncology Agreement

Horizon Discovery (Horizon; Cambridge, United Kingdom) and AstraZeneca (London, United Kingdom) have entered into research collaboration and license agreement to explore a range of oncology-relevant genotypes with the aim of identifying and validating a number of novel drug targets.

Under the terms of the agreement, Horizon will receive an undisclosed upfront payment, and is eligible for subsequent payments of up to USD 88 million in milestones if compounds are developed by AstraZeneca against an undisclosed number of targets identified through the research collaboration.

A defined set of genotypes will be queried by Horizon for synthetic lethality. Horizon will carry out in vitro screening activities using its proprietary small interfering RNA (siRNA) platform. RNAi hits resulting from this first stage will then be validated by Horizon, through techniques including pathway analysis, confirmation of activity in endogenously mutant vs. wild type cell lines (X-MAN), functional assays, or gene knock-in/knockout assays. AstraZeneca may exercise exclusivity over any validated targets.

Synthetic lethality occurs where the combination of mutations in two or more genes leads to cell death, but a mutation in just one of those genes does not. Synthetic lethal screens have demonstrated great potential in oncology, as these pairs of mutations can be used to selectively kill cancer cells, but leave normal cells relatively unharmed.

Horizon’s X-MAN isogenic cell lines accurately model the disease-causing mutations found in patients with cancer, and increasingly in other diseases. Horizon creates the isogenic cell lines using its precision genome-editing GENESIS platform, comprising rAAV, ZFN and CRISPR technologies, to engineer specific disease-related mutations into model cell lines.

These models help scientists understand how complex genetic diseases manifest themselves in patients. They can reduce the cost of bringing to market new personalized therapies by reorganizing many aspects of drug development such as target identification, target validation, assay development, drug screening, lead optimization, and biomarker-driven clinical trial design.

Dr Darrin M Disley, CEO at Horizon Discovery, said: “We are delighted to have extended our relationship with AstraZeneca’s oncology team with this latest agreement. Horizon is uniquely placed in the translational genomics field for investigation of synthetic lethality, as our X-MAN isogenic disease models incorporate patient-relevant genetic context, and allow large scale, timely, and systematic screens for the first time. Combined with our high-throughput RNAi and bioinformatics technology platforms, we have a powerful offering.”

Susan Galbraith, head of the Oncology Innovative Medicines Unit at AstraZeneca, commented: “AstraZeneca’s strategy of collaborating with innovative organizations like Horizon allows us to broaden our oncology research efforts and complement our own internal capabilities.

Partnering Horizon’s excellent capabilities in synthetic lethal screens and validation with our strong oncology discovery and development expertise offers real potential to address the need for novel cancer therapeutics, and ultimately to make a difference to patients.”

Related Links:
Horizon Discovery
AstraZeneca